Dynavax Reports Phase 1B Safety and Immunogenicity Results for Hepatitis B
Therapy Candidate
BERKELEY, CA, Dec 23, 2010 (MARKETWIRE via COMTEX) -- Dynavax Technologies
Corporation (DVAX) today reported safety and immunogenicity data from its Phase
1b clinical trial of DV-601, its proprietary hepatitis B therapeutic vaccine. The
dose escalation study assessed safety and the immunologic and virologic responses
in 14 subjects with chronic hepatitis B infection. The Phase 1b data showed:
--All doses were generally safe and well tolerated; and
--Individual immunologic and virologic responses were observed across
cohorts at all dose levels.
No conclusions regarding the potential clinical impact of the therapy could be
reached in this small study. Dynavax's treatment approach combines both the
surface and core hepatitis B virus (HBV) antigens with ISCOMATRIX(R) adjuvant
originally entered into development by Rhein Biotech prior to its acquisition by
Dynavax in 2006. The candidate vaccine, DV-601, is designed to induce an immune
response against HBV-infected cells and if proven to be safe and effective, may
offer an alternative therapeutic option for patients chronically infected with
HBV.
About Dynavax
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company,
discovers and develops novel products to prevent and treat infectious diseases.
The Company's lead product candidate is HEPLISAV(TM), a Phase 3 investigational
adult hepatitis B vaccine designed to enhance protection more rapidly and with
fewer doses than current licensed vaccines. For more information, visit
dynavax.com.
ISCOMATRIX(R) is a registered trademark of CSL Behring
Contact:
Michael Ostrach
Vice President and Chief Business Officer
510-665-7257
Email Contact
SOURCE: Dynavax Technologies |
